Request Demo

Last update 20 Aug 2025

Cetirizine Hydrochloride

Last update 20 Aug 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryCetirizine hydrochloride, a minuscule molecule drug, operates as an H1 receptor antagonist by targeting the H1 receptor. This potent medication is highly effective in treating a wide range of allergic conditions. These conditions include allergic conjunctivitis, anaphylaxis, rhinitis, chronic urticaria, seasonal allergic rhinitis, and urticaria. Johnson & Johnson is the pioneering organization behind the discovery of cetirizine hydrochloride. Medical approval for this remarkable drug was granted in 1991. Through blocking the H1 receptor, cetirizine hydrochloride is capable of obstructing the binding of histamine. Histamine is the prime cause of various allergic reaction symptoms. Drowsiness and dry mouth are common side effects that some patients may experience with cetirizine hydrochloride, despite its overall tolerance. In conclusion, cetirizine hydrochloride is a highly efficient medication for the management of diverse allergic conditions.

Drug Type

Small molecule drug

Synonyms

Cetirizien Hydrochloride Drops, Cetirizine, Cetirizine Dihydrochloride

+ [46]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [3]

Active Indication

Rhinitis, Allergic, SeasonalConjunctivitis, AllergicDermatitis+ [8]

Inactive Indication

Acute conjunctivitisChronic UrticariaDermatitis, Atopic+ [2]

Originator Organization

Johnson & Johnson

Active Organization

Suzhou Dawnrays Pharmaceutical Co., Ltd.

UCB Japan Co. Ltd.Teva UK Ltd.

+ [7]

Inactive Organization

GSK Plc

McNeil AB

Nicox Ophthalmics, Inc.

+ [7]

License Organization

Apotex, Inc.ITROM Pharmaceutical Group

Santen Pharmaceutical Co., Ltd.

+ [12]

Drug Highest PhaseApproved

First Approval Date

Canada (31 Dec 1991),

Rhinitis, AllergicUrticaria

RegulationPriority Review (China)

Structure/Sequence

Molecular FormulaC21H26Cl2N2O3

InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N

CAS Registry83881-52-1

122

Clinical Trials associated with Cetirizine Hydrochloride

NCT06890260

/ RecruitingNot ApplicableIIT

A Clinical Randomized Controlled Study of Electroacupuncture Combined With Microneedle Knife in the Treatment of Moderate to Severe Allergic Rhinitis

Based on the inclusion and exclusion criteria, patients with allergic rhinitis who meet the requirements are selected as trial subjects, and the efficacy is clarified in a randomized controlled design trial. We will Use the total nasal symptom score as the primary outcome index, serum chemokine, intercellular adhesion molecule-1, eosinophil cationic protein, total non-nasal symptom score, and rhinitis-related quality of life scale as secondary outcome indexes, and oral cetirizine hydrochloride tablets and nasal budesonide spray as the control group, the efficacy of the subjects in the electroacupuncture combined with microneedle knife group and the drug group will be observed respectively before treatment, after 2 weeks of treatment, after 4 weeks, 1 month follow-up after the end of treatment, and 3 months follow-up after the end of treatment. 4 weeks later, 1 month follow-up after the end of treatment and 3 months follow-up after the end of treatment.

Start Date11 Apr 2025

Sponsor / Collaborator

Zhejiang Hospital

CTR20250890

/ CompletedNot Applicable

盐酸西替利嗪干糖浆在健康人体空腹/餐后状态下的生物等效性试验

[Translation] Bioequivalence study of cetirizine hydrochloride dry syrup in healthy volunteers under fasting/fed conditions

主要目的：本研究以海南元盈医药科技有限公司持证的盐酸西替利嗪干糖浆为受试制剂，ユーシービージャパン株式会社生产的盐酸西替利嗪干糖浆（商品名：Zyrtec® Dry Syrup）为参比制剂，进行空腹/餐后状态下人体生物等效性试验，评价受试制剂和参比制剂在健康受试者体内的生物等效性。次要目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main purpose: This study used the cetirizine hydrochloride dry syrup certified by Hainan Yuanying Pharmaceutical Technology Co., Ltd. as the test preparation and the cetirizine hydrochloride dry syrup (trade name: Zyrtec® Dry Syrup) produced by Yushibizapan Co., Ltd. as the reference preparation to conduct a human bioequivalence test under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date28 Mar 2025

Sponsor / Collaborator

Hainan Yuanying Pharmaceutical Technology Co., Ltd.

CTRI/2024/08/072453

/ RecruitingPhase 3

A Prospective, Randomized, Double-blinded, Multi-centric, Two-arm, Parallel-group, Active-Controlled, Phase III Study to Assess the Efficacyand Safety of Cetirizine Ophthalmic in Patients having ocular itching associated with allergic conjunctivitis - NIL

Start Date20 Aug 2024

Sponsor / Collaborator

Akums Drugs & Pharmaceuticals Ltd.

[+1]

100 Clinical Results associated with Cetirizine Hydrochloride

100 Translational Medicine associated with Cetirizine Hydrochloride

100 Patents (Medical) associated with Cetirizine Hydrochloride

3,200

Literatures (Medical) associated with Cetirizine Hydrochloride

01 Nov 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Handheld Spatially Offset Raman Spectroscopy for rapid non-invasive detection of ethylene glycol and diethylene glycol in medicinal syrups

Article

Author: Legge, Isabelle ; Walsby-Tickle, John ; McCullagh, James ; Stokes, Robert ; Bharucha, Tehmina ; Banerjee, Sneha ; Arman, Benediktus Yohan ; Deats, Michael ; Merchant, Hamid A ; Matousek, Pavel ; Newton, Paul N ; Mosca, Sara ; Gangadharan, Bevin ; Caillet, Céline ; Zitzmann, Nicole

We investigate the potential of Spatially Offset Raman Spectroscopy (SORS) as a rapid, non-invasive screening tool deployable in the field to detect diethylene glycol (DEG) and ethylene glycol (EG) in medicinal syrups within closed containers. Measurements were performed on neat propylene glycol (PG) and glycerol, key components of many medicinal syrups, as well as marketed medicinal syrup formulations spiked with DEG and EG at various concentration levels to assess the technique's limit of detection in real-life samples. SORS was able to detect these down to ∼0.5 % concentration level in neat PG for both DEG and EG compounds and ∼1 % concentration level for DEG and EG in neat glycerol. The DEG and EG detection thresholds for the marketed formulations measured through original bottles was ∼1 %, for Benylin (active ingredient: Glycerol) and Piriteze (active ingredient: Cetirizine Hydrochloride). For Calpol (active ingredient: Paracetamol) the detection limit was higher, ∼2 % for EG and ∼5 % for DEG. Although not reaching the International Pharmacopeial 0.1 % detection threshold currently required for purity checks for human consumption, the method can still be used to detect products where DEG or EG has been wrongly used instead of PG or glycerol or if present in large quantities. The technique could also be used for raw material identification testing to ensure no mislabelling has occurred in pre-production stages and as a screening device in distribution chains to detect major deviations from permitted content in non-diffusely scattering, clear formulations, to help prevent serious adverse outcomes, such as acute renal failure and deaths.

01 Nov 2025·NEUROPHARMACOLOGY

Histaminergic transmission potentiates post-traumatic stress-induced expression of anxiety in mice

Article

Author: Patel, Chhatrapal ; Patel, Richa ; Jain, Nishant Sudhir ; Maturkar, Vaibhav ; Vaishnav, Venu Anand Das

Post-traumatic stress is associated with an increased expression of anxiety traits and is reported to be accompanied by altered brain histamine content. However, the contribution of the central histaminergic system in the stress induced anxiety, still remains unclear. Therefore, the present study explored the plausible role of central histaminergic transmission in stress-induced anxiety measures in mice using LDB test and in the expression of CORT, CREB, or BDNF levels in the whole brain, PFC, amygdala, and hippocampus of mice. The mice were exposed to the SPS protocol and subsequently left undisturbed for 7 days. On the 8th day, non-SPS/SPS exposed mice were treated i.c.v with histaminergic agents such as histamine, or histamine precursor, l-histidine, H₁ agonist, FMPH, H₂ agonist, amthamine, H₁ antagonist, cetirizine or H₂ antagonist, ranitidine or H₃ inverse agonist, thioperamide and thereafter evaluated for changes in expression of anxiety followed by estimation of CORT, CREB and BDNF levels in brain. Results revealed that SPS-exposed mice elicit heightened anxiety-like behavior accompanied by increased levels of blood or brain histamine and CORT with reduced BDNF/CREB expression in the all-brain tissues. Administration of histaminergic enhancing agents to SPS-exposed mice potentiated the higher expression of anxiety, also further enhanced CORT, and diminished the BDNF/CREB expression in all brain regions. Conversely, central injection of the H₁ receptor antagonist, cetirizine (0.1 μg/mouse) or H₂ receptor antagonist, ranitidine (10 μg/mouse, i.c.v) to SPS mice completely alleviated all the stressed induced changes while H₃ receptor inverse agonist, thioperamide (2, 10 μg/mouse) failed to affect CORT but restored basal anxiety, CREB and BDNF expression. Thus, the blockade of central histamine H₁/H₂/H₃ receptors might mitigate SPS-induced anxiety-like manifestations by extenuating the SPS-induced CORT, CREB, and BDNF expression.

01 Oct 2025·JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study

Article

Author: Ingles, Lauren ; Weaver, Kelly ; Figg, Lindsay ; Volz, Lesley ; Gunaratnam, Bakeerathan ; Hutchinson, Alexander

Introduction:

Hypersensitivity reactions (HSR) are a known adverse effect of paclitaxel, occurring in approximately 10% of patients, typically during the first or second infusion of the medication. Corticosteroids, histamine-1 and histamine-2 receptor antagonists are given prior to paclitaxel infusions to reduce the incidence of HSR. There are limited data that suggest administration of cetirizine given prior to a platinum infusion as secondary prophylaxis may reduce HSR rates.

Methods:

The objective of this study was to assess the impact of a novel paclitaxel hypersensitivity prevention protocol including high-dose cetirizine administered 12 and 6 h prior to paclitaxel infusion on the rate of HSR compared to a historical control. The primary objective was the rate of HSR of any grade after the first cycle of paclitaxel. Secondary outcomes included grade of infusion reaction and incidence of severe HSR.

Results:

A total of 104 patients were included for analysis in the cetirizine group and 124 in the control group. Hypersensitivity reactions occurred in 37 (16.2%) patients in the overall population, and no statistical difference was observed between groups. (13.46% vs 18.55%; p = 0.23). Numerically more grade 3–4 HSRs occurred in the control group than the treatment group (30.77% vs 69.23; p = 0.51).

Conclusions:

The addition of cetirizine to paclitaxel infusions resulted in numerically lower rates of HSR and a reduction in severity of grade 3–4 HSRs. Future studies with more robust compliance data and a larger patient population would be needed to appropriately assess the efficacy of our novel treatment regimen.

131

News (Medical) associated with Cetirizine Hydrochloride

13 Aug 2025

·www.prnewswire.com

Hay Fever Symptoms? SnizIQ Helps - Naturally

The Slovak Nutraceutical Company LifeBridge Has Concentrated and Optimized Ingredients From Quail Eggs to Effectively and Safely Suppress Allergies Within Minutes of Consumption FORT LAUDERDALE, Fla., Aug. 13, 2025 /PRNewswire/ -- SnizIQ is the only all-natural product on the market with clinically confirmed efficacy against hay fever symptoms. The Serbian nutraceutical brand LifeBridge has taken the proven power of quail eggs and used it to create SnizIQ's unique formulation. This provides targeted concentration for natural allergy relief in as little as 15 minutes. Allergic rhinitis, commonly known as hay fever, is a struggle for many people around the world. In the U.S. alone, around 20% of the population deals with the condition each year. A 2021 study found that over 81 million people deal with allergies on a seasonal basis. Hay fever comes with a variety of unpleasant symptoms, including: Stuffiness and sneezing Wheezing and coughing Itchy nose and sore throat Red and watery eyes Excessive mucus in the nose and throat Along with the obvious physical components, allergic rhinitis often leads to tiredness and headaches. These cold-like symptoms can be difficult to manage and can have a significant impact on an individual's quality of life for weeks and even months at a time. SnizIQ offers a way to manage these symptoms without resorting to stronger synthetic options, like Zyrtec or Claritin. "Stronger pharmaceuticals for allergy relief can be concerning, especially when used for one season after another," explained the CEO and co-founder of LifeBridge, Ladislav. "We don't know many of the side effects, and both tolerance and dependency are concerns. SnizIQ uses the allergy-fighting power of quail eggs to quickly and naturally reduce hay fever symptoms without fear of side effects." SnizIQ has been clinically shown to reduce hay fever symptoms within 15 minutes of consumption. It uses the eggs of the Japanese quail (Coturnix japonica), which contain ovomucoids and ovoinhibitors that are capable of suppressing 200% of the average histamine production in the body. This allows individuals to access quick relief through a product that is formulated with the ideal dosage and concentration for safe, natural, and ongoing allergy relief support. About LifeBridge LifeBridge is a Slovak nutraceutical company that was founded in 2018. It was formed to focus on the distribution of food supplements in Slovakia, the Czech Republic, and Hungary. Its founders bring 30 years of executive experience from across the Pharma Industry, including stints in the C-suite at Roche, Pfizer, and Bayer. LifeBridge uses that past experience to explore natural solutions to common health concerns, from allergies to the immune system and more. Learn more at stopalerg.sk. Ladislav Čižmárik +(421) 908-883317 SOURCE LifeBridge WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

13 Aug 2025

·www.einpresswire.com

Family Allergy & Asthma Research Institute Contributes to Groundbreaking Global Study on Severe Asthma Treatment

FAA Research Institute contributes to global study proving mepolizumab's effectiveness in reducing severe asthma exacerbations Our team’s commitment to advancing asthma care through research is unwavering, showcasing how collaboration and innovation improve patient outcomes.” — Dr. Stephen Pollard LOUISVILLE, KY, UNITED STATES, August 13, 2025 / EINPresswire.com / -- Family Allergy & Asthma (FAA) is proud to announce that Dr. Stephen Pollard, Principal Investigator at the FAA Research Institute, has been published as a co-author in the prestigious Annals of Allergy, Asthma & Immunology. The study, titled “ Mepolizumab Real-World Effectiveness in Severe Asthma with an Eosinophilic Phenotype and Overlapping Severe Allergic Asthma,” represents a significant advancement in the understanding and treatment of severe asthma. This large-scale, real-world study highlights the effectiveness of mepolizumab, a biologic therapy targeting eosinophilic inflammation, in reducing asthma exacerbations in patients with overlapping allergic and eosinophilic phenotypes. The findings provide critical insights for clinicians managing complex asthma cases, where multiple biologic treatment options may be considered. A Team Effort in Research Excellence The success of this study is a testament to the dedication and expertise of the FAA Research Institute team. Research coordinators Becky Whitehead and Amber Noe played a pivotal role in patient recruitment, retention, and data management, ensuring the study’s success. While not listed as authors, their behind-the-scenes contributions were instrumental and reflect the high standards of FAA’s clinical research staff. “Our team’s commitment to advancing asthma care through research is unwavering,” said Dr. Stephen Pollard. “This study is a prime example of how collaboration and innovation can lead to meaningful improvements in patient outcomes.” Join the FAA Research Institute’s Mission Since 1991, the FAA Research Institute has been at the forefront of clinical research, contributing to the development of groundbreaking treatments like Zyrtec, Allegra, Claritin, Flonase, and Nasonex. Located at the Goss Avenue location in Louisville, KY, the institute boasts state-of-the-art technology and a computerized database of over 15,000 patients. The institute collaborates with leading national pharmaceutical and clinical research organizations, ensuring that all studies are closely monitored by the FDA and Institutional Review Boards to prioritize participant safety and rights. Why Participate in Clinical Research? Participants in FAA’s clinical trials benefit from: Personalized care with close monitoring of health conditions. Access to study-related office visits, physician exams, and medications. Reimbursement for time and travel. The opportunity to contribute to advancements in treatments for asthma, allergies, and other conditions. “Our research is fueled by a shared goal to enhance lives through evidence-based findings and innovations,” said Becky Whitehead, Director of Clinical Research. “By joining our studies, participants not only gain access to cutting-edge treatments but also play a vital role in shaping the future of care.” Current Research Opportunities The FAA Research Institute is currently recruiting participants for studies on asthma, food allergies, COPD, dermatitis, and more. To learn more about ongoing trials or to participate, contact the FAA Research Institute at 502.368.0732 or visit familyallergy.com. Advancing Asthma Care Through Cutting-Edge Research Family Allergy & Asthma’s participation in this peer-reviewed publication underscores its dedication to leading-edge research and evidence-based treatment. By contributing to the evolving landscape of biologic therapies for severe asthma, FAA continues to support clinicians and patients in making informed treatment decisions. About Family Allergy & Asthma Research Institute Family Allergy & Asthma is a leading provider of allergy and asthma care, offering comprehensive services to patients across Louisville, KY. With a strong focus on clinical research, FAA is committed to improving the lives of individuals with asthma and allergies through innovative treatments and personalized care. For more information about this study or Family Allergy & Asthma’s research initiatives, please contact Research Department Director Becky White at bwhite@familyallergy.com Becky Whitehead Family Allergy & Asthma +1 502-368-0732 bwhite@familyallergy.com Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical Study

08 Aug 2025

·www.globenewswire.com

Nicox Extends Existing Flexible Equity Financing

Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid-September 2025 August 08, 2025 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced an extension of the PACEO1 equity line of financing entered into with Vester Finance on March 5, 2025, with an additional maximum of 5,000,000 shares (a maximum of 6.43% of the currently issued share capital2 and 4.26% on a fully-diluted basis3). The other terms of the financing, as announced on March 6, 2025, remain unchanged, including the conditions and issue price of the additional shares4.Based on estimated cash and debt positions and expected income from existing agreements, the Company estimates that it is financed into Q3 2026. This cash runway excludes proceeds from the financing announced today but could be further extended depending on the performance of it. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company. Under the terms of the amendment signed on August 7, 2025, Vester Finance agreed to subscribe for an additional maximum of up to 5,000,000 additional shares in the Company, at its own initiative, on terms as set out in the Press Release of March 6, 2025. For information purposes only, at the current share price5, the total gross proceeds of the additional shares in this financing would potentially be €3.1 million. Assuming full use of the extension to this equity line, a shareholder holding 1.00% of Nicox’s capital before the transaction would see a reduction in his stake to 0.94% of the capital. The Company may terminate this agreement at any time without penalty.This transaction was authorized by the Chief Executive Officer using a delegation granted by the meeting of the Board of Directors of August 7, 2025, who themselves used the delegation granted by the General Meeting of the shareholders of the Company on June 27, 2025, under the 13th resolution6. There is no requirement for a prospectus to be submitted to the Autorité des marchés financiers (AMF).Vester Finance, who holds approximately 4% of the share capital, is acting in the capacity as a shareholder of Nicox and also as an investor who may sell all or part of the shares over a short or long period time. Risk FactorsRisks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).The sale of the shares is likely to have an impact on the volatility and liquidity of the stock, as well as on the Company's share price. The number of shares issued under this transaction and admitted to trading will be announced on the Company's website. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa elsewhere. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThis press release and the information contained therein do not constitute an offer to sell or an offer to subscribe, or a solicitation to purchase or to subscribe Nicox's shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons coming into possession of this press release are required to comply with all local regulations applicable to this press release.The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 Programme d’Augmentation de Capital par Exercice d’Options (Capital increase program through exercise of warrants)2 Non-diluted share capital as of 31 July 2025 3 Taking into account the issue of 39,536,771 new shares issuable at the date of this press release on the exercise of stock options (1,187,205 shares), the vesting of restricted stock (4,072,785 shares), the exercise of warrants (20,234,228 shares) and the conversion of bonds convertible into equity (14,042,553 shares)4 The lowest volume-weighted average daily price of the share over the two consecutive trading sessions preceding an exercise request, after applying a maximum discount of 6.5% 5 Closing price of €0.62 on August 7, 20256 Delegation of competence to the Board of Directors to increase the share capital for the benefit of a category of investors without preferential right of subscription of the shareholders Attachment EN_FinancingAugust2025_PR_FINAL

Phase 3

100 Deals associated with Cetirizine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00664	Cetirizine Hydrochloride	R06AE07	DB00341

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis, Allergic	United States	Harrow, Inc.	30 May 2017
Dermatitis	Japan	UCB Japan Co. Ltd.	30 Jun 1998
Eczema	Japan	UCB Japan Co. Ltd.	30 Jun 1998
Pruritus	Japan	UCB Japan Co. Ltd.	30 Jun 1998
Anaphylaxis	China	Suzhou Dawnrays Pharmaceutical Co., Ltd.	01 Jan 1998
Rhinitis	China	Suzhou Dawnrays Pharmaceutical Co., Ltd.	01 Jan 1998
Chronic Urticaria	United States	Johnson & Johnson de Colombia SA	08 Dec 1995
Rhinitis, Allergic, Perennial	United States	Johnson & Johnson de Colombia SA	08 Dec 1995
Rhinitis, Allergic, Seasonal	United States	Johnson & Johnson de Colombia SA	08 Dec 1995
Rhinitis, Allergic	Canada	Pfizer Canada ULC	31 Dec 1991
Urticaria	Canada	Pfizer Canada ULC	31 Dec 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis	NDA/BLA	South Korea	SAMIL PHARMACEUTICAL Co., Ltd.	-
Acute urticaria	Phase 3	United States	JDP Therapeutics LLC	01 Jul 2013
Acute urticaria	Phase 3	Canada	JDP Therapeutics LLC	01 Jul 2013
Acute conjunctivitis	Phase 3	United States	Nicox Ophthalmics, Inc.	01 Mar 2012
Dermatitis, Atopic	Phase 3	-	GSK Plc	01 Aug 2005
Dermatomycoses	Phase 3	-	GSK Plc	01 Aug 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05946551 (CTgov)	Phase 3	Post Acute COVID 19 Syndrome	5	Cetirizine+Famotidine (HRA Treatment Arm)	wsplkttupe = fyyfupujvg nkvyscaqtb (loxgyowalc, vbdzbikdzi - hyvkktpzpa) View more	-	17 Jul 2025
				Famotidine Placebo (Placebo Arm)	wsplkttupe = ryagsmubbn nkvyscaqtb (loxgyowalc, kkqpambepb - olbtfrqvqx) View more
NCT06039137 (H1-Switch Study, Pubmed \| JCO Oncol Pract)	Not Applicable	-	-	Intravenous Clemastine	kbvqyjebzp(ytoufarecc) = rciokivdye srzvohyfvz (vismmfoyzk, -3.4 to 1.1)	Positive	07 Jun 2024
				Oral Cetirizine	kbvqyjebzp(ytoufarecc) = zrphdddvlq srzvohyfvz (vismmfoyzk, -3.4 to 1.1)
NCT02023164 (CTgov)	Phase 3	Acute urticaria	36	JDP-205 (Test Drug)	oxnhibnqor(uvgtkaxzwh) = obvfwqupbv ecnmeccvut (ylekqselhu, 0.61) View more	-	09 Feb 2024
				Diphenhydramine (Control)	oxnhibnqor(uvgtkaxzwh) = aiqbwfxjfq ecnmeccvut (ylekqselhu, 0.89) View more
NCT02865018 (CTgov)	Phase 1/2	Neuromyelitis Optica	16	cetirizine	ftyfxqvjym(fgxlwywqwr) = odchpuijvy ounqvpxyeg (fqhalmxjzp, 0.80) View more	-	07 Jun 2023
PRECEPT (ECTRIMS2022)	Phase 3	-	20	Cetirizine 10mg	xeceutiuao(qbyxtkmvjp) = fkahaqrkxr yzfmwqceah (yrckwkspez )	Positive	12 Oct 2022
				Diphenhydramine 25mg	xeceutiuao(qbyxtkmvjp) = oqxpifvhty yzfmwqceah (yrckwkspez )
NCT04189588 (versus, CTgov)	Phase 2	Hypersensitivity \| Neoplasms	34	Cetirizine HCl 10 mg/mL+Paclitaxel+Rituximab (Cohort A)	zzgssaiepk = fcmhsezgbt fsbqhxfzel (mhzxmtktba, alwncnxcmq - kzeyhkfefd) View more	-	17 May 2022
				Paclitaxel+Diphenhydramine 50 mg/mL+Rituximab (Cohort B)	zzgssaiepk = whxjekwjyo fsbqhxfzel (mhzxmtktba, uxzyfojqft - yavnwlnhjp) View more
NCT04189588 (ASCO2021)	Phase 2	Hypersensitivity	34	IV cetirizine 10 mg	mnvgzdzmqo(ipqqddcdnc) = gbuxbyxepy zknggqnuwk (dufvfuuklc ) View more	-	28 May 2021
				IV diphenhydramine 50 mg	mnvgzdzmqo(ipqqddcdnc) = fmiwljwysv zknggqnuwk (dufvfuuklc ) View more
NCT02935699 (Pubmed \| Ann Emerg Med)	Phase 3	Acute urticaria	262	Intravenous Cetirizine 10 mg	qyqcfrhzrx(krhfjijjgv) = bsjxwoavqg ublmmppakg (pfcrvcggpe ) View more	Positive	08 Jul 2020
				Intravenous Diphenhydramine 50 mg	qyqcfrhzrx(krhfjijjgv) = oxawtajlpl ublmmppakg (pfcrvcggpe ) View more
NCT03192488 (CTgov)	Phase 4	Hypoxia	13	Cetirizine (Cetirizine and Hypoxia)	aqzjbgbjln(sgpqjgyfvy) = yjllxlvlis bszneaasob (ljnmffydig, 1.92) View more	-	16 Jun 2020
				Placebo (Placebo and Hypoxia)	aqzjbgbjln(sgpqjgyfvy) = umxlmogjqr bszneaasob (ljnmffydig, 2.87) View more
NCT02935699 (CTgov)	Phase 3	Acute urticaria	262	Test Drug (JDP-205) (Test Drug)	cyhsqegrty(yhjcciibed) = suxdodejbt swjqpodgty (nzaagoukun, 0.944) View more	-	27 Nov 2019
				Diphenhydramine (Control)	cyhsqegrty(yhjcciibed) = getbumhekg swjqpodgty (nzaagoukun, 0.984) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis